Aptose Biosciences Inc (APTO)

HEALTH CARE: PHARMACEUTICALS
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

251 CONSUMERS ROAD TORONTO, ONTARIO, CANADA M2J 4R3

Lorus Therapeutics is a biopharmaceutical company. Co. is engaged in the discovery, research and development of novel anticancer therapies with a safety profile. Co. has worked to establish a marketable anticancer product pipeline, with products in various stages of development ranging from discovery and pre-clinical to preparation for initiation of a Phase III clinical trial. Co. is considered to be in the development stage.

Data as of 2020-08-01
Market Cap439.075 Million Shares Outstanding76.299 Million Avg 30-day Volume1.065 Million
P/E Ratio Dividend Yield EPS-0.77
Price/Sales Price cash flow ratio Price free cash flow ratio-40.4
Book Value0.48 Price to Tangible Book22.74 Alpha0.01
Short Interest Ratio % Short Interest to Float R-squared0.075762
BETA1.51837 52-week High/Low9.2525 / 1.82 Stddev0.23734
View SEC Filings from APTO instead.
Q1 2020 All Institutions Hedge Funds 1
Filers who had this stock in their top 10: 3 2 (0.13%)
13F Filers holding this stock: 56 20 (1.31%)
Aggregate 13F shares on 03/31/2020: 35.233 Million 27.095 Million
Aggregate 13F shares on 12/31/2019: 30.706 Million 22.453 Million
Percent change: 14.74% 20.67%
Funds creating new positions: 19 5
Funds Adding to an existing position: 18 10
Funds closing out their position: 21 12
Funds reducing their position: 10 4
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding APTO (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding APTO BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

414.3 Thousand total shares from 8 transactions

Exercise Derivative Conversion (M)

25 Thousand total shares from 6 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

CHOW GREGORY K. EXECUTIVE VP & CFO

  • Officer
232,846 2020-07-10 4

RICE WILLIAM G. CHAIR, PRESIDENT & CEO

  • Officer
  • Director
297,523 2020-07-10 6

MARANGO JOTIN SENIOR VP, CHIEF BUS. OFFICER

  • Officer
116,219 2020-07-10 5

WHITEHEAD WARREN

  • Director
40,000 2020-06-23 4

LOEWY CAROLINE M

  • Director
0 2020-06-03 3

BURGER DENIS R

  • Director
0 2020-03-13 3

PLATZER ERICH

  • Director
0 2020-03-11 2

VINCENT MARK D.

  • Director
0 2020-03-11 3

ASHE CAROL GAIL

  • Director
0 2020-03-11 2

BEJAR RAFAEL SR. VP, CHIEF MEDICAL OFFICER

  • Officer
0 2020-01-31 3

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

CHOW GREGORY K. - Officer EXECUTIVE VP & CFO

2020-07-10 S 126,668 $6.05 d 232,846 232,846.00 direct

MARANGO JOTIN - Officer SENIOR VP, CHIEF BUS. OFFICER

2020-07-10 S 62,835 $6.05 d 116,219 116,219.00 direct

RICE WILLIAM G. - Director - Officer CHAIR, PRESIDENT & CEO

2020-07-10 S 168,891 $6.05 d 297,523 297,523.00 direct

MARANGO JOTIN - Officer SENIOR VP, CHIEF BUS. OFFICER

2020-07-02 S 20,946 $6.34 d 179,054 179,054.00 direct

WHITEHEAD WARREN - Director

2020-06-24 M 5,000 a 0 40,000.00 direct

WHITEHEAD WARREN - Director

2020-06-24 S 12,000 $6.73 d 45,000 40,000.00 direct

WHITEHEAD WARREN - Director

2020-06-24 M 7,000 $2.60 a 57,000 40,000.00 direct

WHITEHEAD WARREN - Director

2020-06-24 M 7,000 a 53,000 40,000.00 direct

WHITEHEAD WARREN - Director

2020-06-24 S 5,000 $6.78 d 40,000 40,000.00 direct

WHITEHEAD WARREN - Director

2020-06-24 M 5,000 $1.02 a 50,000 40,000.00 direct

WHITEHEAD WARREN - Director

2020-06-23 M 1,250 $1.91 a 51,250 40,000.00 direct

WHITEHEAD WARREN - Director

2020-06-23 M 500 a 0 40,000.00 direct

WHITEHEAD WARREN - Director

2020-06-23 S 5,000 $7.17 d 45,000 40,000.00 direct

WHITEHEAD WARREN - Director

2020-06-23 M 1,250 $4.22 a 53,000 40,000.00 direct

WHITEHEAD WARREN - Director

2020-06-23 M 10,000 a 0 40,000.00 direct

WHITEHEAD WARREN - Director

2020-06-23 M 1,250 a 0 40,000.00 direct

WHITEHEAD WARREN - Director

2020-06-23 S 13,000 $7.08 d 50,000 40,000.00 direct

WHITEHEAD WARREN - Director

2020-06-23 M 500 $1.60 a 51,750 40,000.00 direct

WHITEHEAD WARREN - Director

2020-06-23 M 1,250 a 0 40,000.00 direct

WHITEHEAD WARREN - Director

2020-06-23 M 10,000 $1.12 a 63,000 40,000.00 direct
Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments